

## Takeda unveils advanced prophylaxis treatment for haemophilia patients

16 May 2022 | News

An extended half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A, resulting in lower weekly infusion rates than standard FVIII, providing excellent prophylactic coverage



Takeda Pharmaceutical Company has launched Adynovate, an innovative extended half-life recombinant Factor VIII (rFVIII) treatment, using established technology (controlled PEGylation), for haemophilia A patients in India.

Adynovate in combination with MYPKFIT, the first and only FDA approved application offers a personalised and interactive prophylaxis treatment option that enables both healthcare professionals (HCPs) and patients in real-time to monitor factor VIII levels. Alerts are sent to patients on prophylaxis when their estimated factor VIII levels are low and remind them when their infusions are due, thereby providing excellent prophylactic coverage.

Administered in three steps with BAXJECT III system, Adynovate eliminates the need to disinfect the vial, as vials are already assembled in the system housing. It can be stored at room temperature not to exceed 30°C (86°F) for a period of up to three months not to exceed the expiration date thereby easing the handling and storing process.